A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B (ACTRN12625000204448)

CLB-4000-1-001

This trial is Currently recruiting
Registration number ACTRN12625000204448
A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B

Program & service

This trial is being run with the Specialty Medicine service, and as part of the Gastroenterology program.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Stuart Roberts

Key inclusion data

You may be eligible for this study if you are an adult aged between 18 and 60 years old with chronic hepatitis B.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.